PATENT CLAIM ANALYSIS

Application Number: 15984410
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "234200"]

Abstract:
The present invention discloses a novel use of a pharmaceutical composition in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction, in particular to the use of AC1 inhibitor NB001 and AC1&8 mixed inhibitors NB010 and NB011 in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction.

Claim (Index 1):
A pharmaceutical composition for treating pain, comprising:\n opioids, and at least one selected fro the group consisting of NB001, NB010, or NB011, the NB001, i.e., 5-((2-(6-amino-9H-purin-9-yl)ethyl)amino)pentane-1-ol, has the following structure: the NB010, i.e., 6-amino-9-(2-p-methoxy-ethyl)-9H-purine-8-thiol, has the following chemical structure: the NB011, i.e., 4-(9H-purin-6-yl)morpholine (also known as 6-morpholin-4-yl-7H-purine) has the following chemical structure:

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.84375
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15651564', '12083358', '14239461', '12600503', '14391658']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7420538044872326
- 35 USC 102 Novelty (BERT): 0.5155467643429104
- Combined Prediction Score: 0.7194031004728003
- Mean Citation Score: 204.428564
- Max Citation Score: 245.85503
- Similarity Product: 136.58475680514928

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test